(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
0.75% HKD 6.76
Live Chart Being Loaded With Signals
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally...
Stats | |
---|---|
Tagesvolumen | 39.72M |
Durchschnittsvolumen | 39.84M |
Marktkapitalisierung | 80.28B |
EPS | HKD0 ( 2024-03-19 ) |
Nächstes Ertragsdatum | ( HKD0.150 ) 2024-05-22 |
Last Dividend | HKD0.140 ( 2023-09-07 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 12.75 |
ATR14 | HKD0.00900 (0.13%) |
Volumen Korrelation
CSPC Pharmaceutical Group Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
CSPC Pharmaceutical Group Korrelation - Währung/Rohstoff
CSPC Pharmaceutical Group Finanzdaten
Annual | 2023 |
Umsatz: | HKD34.75B |
Bruttogewinn: | HKD24.51B (70.51 %) |
EPS: | HKD0.550 |
FY | 2023 |
Umsatz: | HKD34.75B |
Bruttogewinn: | HKD24.51B (70.51 %) |
EPS: | HKD0.550 |
FY | 2022 |
Umsatz: | HKD35.98B |
Bruttogewinn: | HKD25.88B (71.94 %) |
EPS: | HKD0.590 |
FY | 2021 |
Umsatz: | HKD27.87B |
Bruttogewinn: | HKD21.14B (75.84 %) |
EPS: | HKD0.470 |
Financial Reports:
No articles found.
CSPC Pharmaceutical Group Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.100 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.110 (N/A) |
HKD0.140 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0365 | 2003-08-28 |
Last Dividend | HKD0.140 | 2023-09-07 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 21 | -- |
Total Paid Out | HKD1.673 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.34 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.14 | |
Div. Directional Score | 8.76 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9869.HK | Ex Dividend Junior | 2023-09-19 | Insufficient data to determine frequency | 0 | 0.00% | |
2130.HK | Ex Dividend Knight | 2023-06-16 | Semi-Annually | 0 | 0.00% | |
1126.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
0189.HK | Ex Dividend Junior | 2023-06-14 | Annually | 0 | 0.00% | |
3836.HK | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
1710.HK | Ex Dividend Junior | 2023-09-25 | Annually | 0 | 0.00% | |
0737.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
2314.HK | Ex Dividend Junior | 2023-08-11 | Semi-Annually | 0 | 0.00% | |
1278.HK | Ex Dividend Junior | 2023-08-28 | Sporadic | 0 | 0.00% | |
0327.HK | Ex Dividend Knight | 2023-09-01 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.189 | 1.500 | 6.23 | 9.34 | [0 - 0.5] |
returnOnAssetsTTM | 0.150 | 1.200 | 5.01 | 6.01 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.62 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.533 | -1.000 | 4.67 | -4.67 | [0 - 1] |
currentRatioTTM | 2.63 | 0.800 | 1.867 | 1.494 | [1 - 3] |
quickRatioTTM | 2.27 | 0.800 | 1.336 | 1.069 | [0.8 - 2.5] |
cashRatioTTM | 1.180 | 1.500 | 4.56 | 6.83 | [0.2 - 2] |
debtRatioTTM | 0.0151 | -1.500 | 9.75 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 362.23 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.701 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.369 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0210 | -1.500 | 9.92 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.707 | 1.000 | 1.551 | 1.551 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.232 | 1.000 | 7.36 | 7.36 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 10.82 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.794 | 0.800 | 8.04 | 6.43 | [0.5 - 2] |
Total Score | 11.38 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.49 | 1.000 | 9.04 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.11 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.369 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.70 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.701 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.533 | 1.500 | 4.67 | -4.67 | [0 - 1] |
pegRatioTTM | 0.300 | 1.500 | -1.335 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.205 | 1.000 | 7.37 | 0 | [0.1 - 0.5] |
Total Score | 6.14 |
CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.